Ardelyx logo

ArdelyxNASDAQ: ARDX

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

19 June 2014

Next earnings report:

21 February 2025

Last dividends:

N/A

Next dividends:

N/A
$1.13 B
-49%vs. 3y high
75%vs. sector
-vs. 3y high
-vs. sector
-50%vs. 3y high
88%vs. sector
-92%vs. 3y high
59%vs. sector

Price

pre-market | 6 min ago
$4.79+$0.02(+0.42%)

Dividend

No data over the past 3 years
$98.24 M$108.57 M
$98.24 M-$809.00 K

Analysts recommendations

Institutional Ownership

ARDX Latest News

Ardelyx to Participate at the Piper Sandler 36th Annual Healthcare Conference
globenewswire.com20 November 2024 Sentiment: -

WALTHAM, Mass., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that Justin Renz, Chief Financial and Operations Officer, and Eric Foster, Chief Commercial Officer, will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, December 4, 2024 at 12:30pm EST in New York City.

Ardelyx Responds to District Court Decision Granting Motion to Dismiss
globenewswire.com08 November 2024 Sentiment: NEGATIVE

Inclusion of oral-only phosphate-lowering therapies in the ESRD PPS will put dialysis patients' health at risk Inclusion of oral-only phosphate-lowering therapies in the ESRD PPS will put dialysis patients' health at risk

Ardelyx to Participate at the 2024 Jefferies London Healthcare Conference
globenewswire.com05 November 2024 Sentiment: POSITIVE

WALTHAM, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that Michael Raab, President and CEO, Justin Renz, Chief Financial and Operations Officer and Eric Foster, Chief Commercial Officer, will participate in a fireside chat at the 2024 Jefferies London Healthcare Conference on Tuesday, November 19, 2024 at 12:30pm GMT / 7:30am EST in London.

Ardelyx, Inc. (ARDX) Q3 2024 Earnings Call Transcript
seekingalpha.com31 October 2024 Sentiment: POSITIVE

Ardelyx, Inc. (NASDAQ:ARDX ) Q3 2024 Earnings Conference Call October 31, 2024 4:30 PM ET Company Participants Caitlin Lowie - Vice President of Corporate Communications & Investor Relations Michael Raab - President & Chief Executive Officer Eric Foster - Chief Commercial Officer Justin Renz - Chief Financial Officer & Chief Operations Officer Conference Call Participants Louise Chen - Cantor Fitzgerald Dennis Ding - Jefferies Roanna Ruiz - Leerink Partners Laura Chico - Wedbush Joseph Thome - TD Cowen Ryan Deschner - Raymond James Matt Kaplan - Ladenburg Thalmann Chris Raymond - Piper Sandler & Co. Operator Good afternoon, ladies and gentlemen and welcome to the Ardelyx Third Quarter 2024 Earnings Call. Our host for today's call is Caitlin Lowie, Vice President of Corporate Communications and Investor Relations at Ardelyx.

Compared to Estimates, Ardelyx (ARDX) Q3 Earnings: A Look at Key Metrics
zacks.com31 October 2024 Sentiment: NEUTRAL

The headline numbers for Ardelyx (ARDX) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Ardelyx (ARDX) Reports Break-Even Earnings for Q3
zacks.com31 October 2024 Sentiment: POSITIVE

Ardelyx (ARDX) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to earnings of $0.03 per share a year ago.

Ardelyx Reports Third Quarter 2024 Financial Results and Provides Business Update
globenewswire.com31 October 2024 Sentiment: POSITIVE

IBSRELA generates $40.6 million in net product sales revenue; Company expects full year 2024 IBSRELA net sales revenue to be between $145 and $150 million

Ardelyx Presents Results from its IBS in America 2024 Supplemental Survey at the American College of Gastroenterology's (ACG) Annual Meeting
globenewswire.com28 October 2024 Sentiment: POSITIVE

Ninety percent of survey participants reported “some” or “significant” negative impact of IBS-C on their life Survey results presented in two poster presentations WALTHAM, Mass., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that results from the IBS in America 2024 supplemental survey, in partnership with Health Union, were presented at the American College of Gastroenterology's (ACG) Annual Scientific Meeting & Postgraduate Course, currently taking place in Philadelphia.

Ardelyx Announces Launch of Gut Matters: Discoveries and Innovations, a New Podcast for the IBS-C Patient Community
globenewswire.com22 October 2024 Sentiment: POSITIVE

WALTHAM, Mass., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced the launch of Gut Matters: Discoveries and Innovations, a new podcast for the irritable bowel syndrome with constipation (IBS-C) patient community. The podcast is hosted by Ardelyx's director, patient advocacy, Johannah Ruddy, M.Ed. and practicing gastroenterologist, Andrea Shin, MD. The first episode is out now. Each month, the hosts will be joined by patients, caregivers, advocacy leaders, healthcare providers and other gastroenterology experts to discuss the impact of IBS-C and provide education and hope for those affected.

Ardelyx to Report Third Quarter 2024 Financial Results on October 31, 2024
globenewswire.com17 October 2024 Sentiment: POSITIVE

WALTHAM, Mass., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced it will hold a conference call on Thursday, October 31, 2024, at 4:30 p.m.

What type of business is Ardelyx?

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

What sector is Ardelyx in?

Ardelyx is in the Healthcare sector

What industry is Ardelyx in?

Ardelyx is in the Biotechnology industry

What country is Ardelyx from?

Ardelyx is headquartered in United States

When did Ardelyx go public?

Ardelyx initial public offering (IPO) was on 19 June 2014

What is Ardelyx website?

https://www.ardelyx.com

Is Ardelyx in the S&P 500?

No, Ardelyx is not included in the S&P 500 index

Is Ardelyx in the NASDAQ 100?

No, Ardelyx is not included in the NASDAQ 100 index

Is Ardelyx in the Dow Jones?

No, Ardelyx is not included in the Dow Jones index

When was Ardelyx the previous earnings report?

No data

When does Ardelyx earnings report?

The next expected earnings date for Ardelyx is 21 February 2025